| Literature DB >> 29607397 |
Petros C Benias1, Lionel D'Souza2, Gloria Lan2, Craig Gluckman2, Sumant Inamdar1, Arvind J Trindade1, Larry S Miller1, David L Carr-Locke3.
Abstract
BACKGROUND AND STUDY AIMS: Current endoscopic therapies for gastroesophageal reflux disorder (GERD) are limited by technical complexity, and/or cost. We sought to evaluate the success of a novel resection and plication (RAP) anti-reflux procedure. PATIENTS AND METHODS: RAP was performed on 10 patients with GERD refractory to proton pump inhibitor (PPI) therapy. RAP consists of semi-circumferential mucosectomy along with full-thickness plication of the lower esophageal sphincter (LES) and cardia. We assessed the technical success and safety as well as followed GERD-Health Related Quality of Life (GERD-HRQL) scores and medication usage.Entities:
Year: 2018 PMID: 29607397 PMCID: PMC5876037 DOI: 10.1055/s-0044-101453
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1 Conceptual diagram of a RAP anti-reflux procedure. a Retroflexed view of a patient with a small hiatus hernia, b followed by mucosal resection along the aspect of the greater curvature at the level of the GEJ, and c finally a full-thickness plication according to a predetermined suture pattern, d with an improved appearance on retroflexion.
Patient characteristics.
| Subject | PPI use | GERD-HRQL | Supporting studies | Esophagitis | Hiatus hernia/ Hill grade | Duration of follow-up | GERD-HRQL | PPI use |
| 1 | 40 mg PPI BID | 36 | Barium esophagram | Grade A | 1 cm/ 1 | 24 months | 8 | H2B daily |
| 2 | 20 mg PPI BID | 25 | Barium esophagram | Grade A | 1 cm/ 2 | 21 months | 1 | None |
| 3 | 40 mg PPI + H2B daily | 22 | Barium esophagram | Grade A | 1 cm/ 1 | 16 months | 2 | None |
| 4 | 40 mg PPI +H2B daily | 30 | Barium esophagram | Grade A | 2 cm/ 2 | 15 months | 4 | H2B PRN |
| 5 | 40 mg PPI daily | 27 | Barium esophagram | Grade A | 2 cm/ 2 | 7 months | 2 | None |
| 6 | 40 mg PPI daily | 27 | Barium esophagram | Grade B | 2 cm/ 2 | 9 months | 4 | None |
| 7 | 40 mg PPI BID | 25 | Barium esophagram | Grade A | 2 cm/ 2 | 9 months | 4 | None |
| 8 | 40 mg PPI daily | 25 | Barium esophagram | Grade B | 2 cm/ 3 | 6 month | 8 | PPI 20 mg daily |
| 9 | 40 mg PPI daily | 25 | Barium esophagram | Grade B | 1 cm/ 1 | 5 month | 5 | None |
| 10 | 40 mg BID + H2B | 24 | Barium esophagram | None | 1 cm/ 1 | 5 month | 5 | PPI 20 mg (intermittent use) |
PPI, proton pump inhibitor; GERD-HRQL, GERD-Health Related Quality of Life; H2B, H2 blocker; BID,
PPI is indicated in milligrams of omeprazole equivalents
Fig. 2 Endoscopic appearance of RAP in patients with intermediate and long-term follow-up. a Patient 1 with small HH with follow-up endoscopy at 3.5 months, b showing improved LES and valvular appearance. c Patient 2 with small HH and d with follow-up at 2 years showing durable endoscopic improvement which correlated with her symptom scores.
Fig. 3 Change over time on GERD-HRQL scores on a per-patient basis.